Aperture Investors Hires Nick Turgeon to Launch and Lead Asset-Based Finance Strategy
The strategy will launch with significant seed capital from Generali Investments, the asset management arm of the Generali Group, and is already attracting strong interest from third-party investors, targeting an initial strategy size of $1 billion. Initially focused on asset-based finance opportunities in North America, the strategy aims to expand into European credit markets over time. Built around flexible capital that can grow alongside leading originators, it maintains a focused footprint to ensure selectivity and disciplined deployment—positioning Aperture to access differentiated opportunities and align with investors' long-term objectives.
Turgeon brings deep experience in sourcing, analyzing, structuring, and managing asset-based finance investments. Most recently, he was a managing director on the Specialty Finance team at Castlelake, a global alternative investment firm, where he spent eight years. Prior to that, he worked in the leveraged finance group at U.S. Bank, managing private equity sponsor transactions. He began his career in fixed income sales and trading at Piper Sandler (formerly Piper Jaffray).
'We're excited to welcome Nick Turgeon to lead this new strategy at a pivotal time for asset-based finance within the evolving private credit landscape,' said Peter Kraus, CEO and Chairman of Aperture. 'Nick brings the right experience to lead this effort, and his appointment reflects our broader commitment to expanding in segments of the private credit market where flexible, well-underwritten capital is in demand.'
'Aperture offers the right foundation to build a focused asset-based finance strategy at a time when traditional lenders are retrenching and financing needs are becoming more nuanced," said Turgeon. 'Our approach is grounded in disciplined investing, with a focus on understanding asset-level fundamentals and structuring capital solutions that are responsive to the needs of originators while maintaining a strong emphasis on risk and alignment.'
With the launch of the Asset-Based Finance strategy, Aperture now manages more than $2.3 billion in committed capital across its alternative credit platform. It also marks the latest milestone in a period of significant growth for the firm, following the introduction of its Structured Credit strategy in January 2025 and Litigation Finance strategy in September 2024.
About Aperture Investors
Aperture Investors is an alternative asset manager overseeing approximately $5.2 billion in assets under management and committed and seed capital (as of June 30, 2025). Founded in partnership with Generali Group, a leading global insurance and asset management group, Aperture combines the entrepreneurial agility of a boutique with the institutional strength of a global platform. With investment strategies spanning public and private markets, Aperture's top-tier portfolio managers and teams deliver alpha-focused investment solutions, with a commitment to transparency and client alignment. For more information, visit us at www.apertureinvestors.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indianapolis Star
16 minutes ago
- Indianapolis Star
Eli Lilly happy with weight loss pill performance as drugmaker races to be the first to market
Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market, company officials announced August 7. In a clinical trial, the company's weight loss pill led to a nearly 12% weight loss at 72 weeks for participants who took the highest dose of the medicine. The trial that included more than 3,000 people is one of two late-stage trials the drug must pass before Lilly can submit the pill for federal approval, which CEO David Ricks said Thursday he expects the company to do by the end of the year. Lilly reported that participants lost an average of 27 pounds on the once-daily pill, named orforglipron, comparable to other GLP-1 injectable medicines like Zepbound and Mounjaro. The safety of the pill was also equivalent to other GLP-1s, Lilly said. For Lilly, the clinical results are a positive sign for its oral weight loss pill that the company hopes will be as successful as the injectable drugs booming the weight loss industry. It would likely be the first GLP-1 oral drug for weight loss. But in the eyes of some investors and doctors, the clinical results fell short. Investors were hoping for results closer to 15% weight loss and expressed concern about the number of people who dropped out of the trial. Around 12% of people left the trial due to side effects or personal reasons. Ricks cautioned that people can quit a trial for a number of reasons and said the results of the pill matched Lilly's expectations for the medicine. Other medicines in the same drug class are shown to result in as much as 20% in weight loss. "We're not disappointed with these results, it's right on thesis for us," Ricks said on CNBC in an interview before the earnings call. "The goal was to create an oral pill that was convenient and can be made at huge scale for the mass market and had weight loss that was competitive... and that's what we've achieved." Shares of Lilly fell around 14% on Aug. 7. Lilly's obesity pill works similarly to Zepbound, an injectable offered by Lilly, by targeting gut hormones to promote weight loss. The Indianapolis drugmaker is hoping to expand access to weight loss drugs by offering an oral medication. European rival Novo Nordisk, the company behind the injectable drug Wegovy, is also developing an obesity pill, but Lilly is considered to be in the lead to bring an oral medication to market. By this time next year, Lilly could be producing the drug, Ricks said. Lilly reported 38% year-over-year revenue growth on Aug. 7, raising the company's outlook for 2025 amid what has been a rollercoaster year so far. Earlier in the week, President Donald Trump threatened to levy tariffs of up to 250% on drugs imported into the United States. The president told CNBC on Aug. 5 that he plans to announce new tariffs "within the next week or so" on pharmaceuticals. A few months ago, Ricks strongly cautioned President Trump about the adverse effects that the administration's retaliatory tariffs could have on U.S. drug manufacturers who export popular medicines and the rest of the industry. Lilly operates large manufacturing hubs overseas in Europe and could face higher prices to bring their own drugs back to the United States. To increase domestic production, Lilly is building four new manufacturing facilities in the U.S. through a $27 billion investment. Lilly hopes the facilities will make medicine for patients within the next five years. Investors did not ask about tariffs on the Aug. 7 earnings call, rather focusing on how Lilly plans to approach drug reform pricing. Trump has instructed 17 drug companies, including Lilly, to take steps to address what he calls "abusive drug pricing practices" by Sept. 29. Ricks told investors Lilly is in talks with the administration to bring down drug prices for the average American. As of now, Lilly has not reported a huge disruption in revenue caused by tariff policies. In Q2, Lilly reported:
Axios
44 minutes ago
- Axios
Witkoff to brief Ukrainian and NATO officials on Putin meeting
White House envoy Steve Witkoff plans to hold a video conference on Thursday with senior officials from Ukraine, Finland, France, Germany, Italy and the U.K. to brief them on his meeting with Russian President Vladimir Putin and discuss the path forward, including a possible Trump-Putin summit, according to two sources with direct knowledge. Why it matters: President Trump was moving toward a much tougher position on Russia, but pivoted after the Trump-Witkoff meeting to talking optimistically about the "progress" being made and the possibility of a summit with Putin. Behind the scenes: Trump held a call with Ukrainian President Volodymyr Zelensky and other European leaders on Wednesday and told them about the possibility of a meeting between him and Putin, and a trilateral summit afterwards including Zelensky. That call left confusion in Kyiv and other European capitals. Officials were uncertain whether U.S. policy was changing, or whether sanctions would still be announced on Friday as Trump had planned. The intrigue: Ukrainian officials say they are concerned Putin's proposal for a meeting with Trump is a way for him to try and reach agreements with the U.S. directly about ending the war, without Ukraine or the European powers having a say. The White House didn't immediately respond to questions about Witkoff's planned conference call. Driving the news: Putin said Thursday that there was mutual interest in a summit with Trump, but the Kremlin cast doubt on the U.S. proposal for a trilateral summit with Zelensky. What's next: Trump announced Wednesday that he would double tariffs on India to 50%, effective August 27, over the country's purchases of Russian oil.
NBC News
2 hours ago
- NBC News
Live updates: U.S. tariffs go into effect; Russia says Putin will meet with Trump on Ukraine
What to know today... TRUMP TARIFFS: President Donald Trump's sweeping tariffs took effect today just after midnight ET, affecting everything from European appliances and Japanese cars to a slew of goods from China. MANUFACTURING BOON? Treasury Secretary Scott Bessent said in an interview on MSNBC that tariffs should spur more U.S. manufacturing, which Trump has said is a key goal of his global trade reset. Markets, meanwhile, were up slightly this morning as tariffs kicked in. TRUMP-PUTIN MEETING: The Kremlin said Vladimir Putin and Trump will meet in the "coming days" after the U.S. president said he hoped to discuss ending the war in Ukraine in person with his Russian counterpart. REDISTRICTING FIGHT: A decade of Supreme Court rulings has set the stage for the fight over redistricting in Texas and the unfolding responses in several other states that are now looking to redraw their congressional maps as well.
